Recent results from the PATHFINDER 2 study showed that the addition of GRAIL’s multi-cancer detection test to standard screening led to a seven-fold increase in cancers detected within a year, the company said.
Exact Sciences Corp. announced the launch of the Cancerguard test, a multi-cancer early detection blood test that is now available as a laboratory-developed test in the United States.
